Intra-Cellular Therapies Inc (NASDAQ:ITCI) EVP Andrew Satlin sold 11,573 shares of Intra-Cellular Therapies stock in a transaction on Thursday, January 9th. The stock was sold at an average price of $26.16, for a total transaction of $302,749.68. Following the completion of the transaction, the executive vice president now owns 22,911 shares in the company, valued at approximately $599,351.76. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Shares of ITCI stock traded up $0.47 during mid-day trading on Friday, reaching $25.90. The stock had a trading volume of 2,709,342 shares, compared to its average volume of 4,080,563. The stock’s 50-day moving average price is $19.33 and its two-hundred day moving average price is $11.95. Intra-Cellular Therapies Inc has a 52-week low of $6.75 and a 52-week high of $43.56. The firm has a market capitalization of $1.46 billion, a PE ratio of -9.12 and a beta of 1.96. The company has a current ratio of 7.77, a quick ratio of 7.77 and a debt-to-equity ratio of 0.09.
Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.17. On average, equities research analysts forecast that Intra-Cellular Therapies Inc will post -2.85 earnings per share for the current year.
A number of research firms have issued reports on ITCI. BTIG Research boosted their price objective on shares of Intra-Cellular Therapies from $34.00 to $73.00 and gave the company a “buy” rating in a research report on Monday, December 23rd. Zacks Investment Research upgraded shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $34.00 price objective on the stock in a research report on Wednesday. ValuEngine cut shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Canaccord Genuity boosted their price objective on shares of Intra-Cellular Therapies from $29.00 to $65.00 and gave the company a “buy” rating in a research report on Monday, December 23rd. Finally, BidaskClub cut shares of Intra-Cellular Therapies from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $36.25.
About Intra-Cellular Therapies
Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disorders. The company is developing its lead drug candidate, lumateperone for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases.
Further Reading: S&P/ASX 200 Index
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.